Butanamide
Butanamide structure
|
Common Name | Butanamide | ||
|---|---|---|---|---|
| CAS Number | 541-35-5 | Molecular Weight | 87.120 | |
| Density | 0.9±0.1 g/cm3 | Boiling Point | 216.0±0.0 °C at 760 mmHg | |
| Molecular Formula | C4H9NO | Melting Point | 114-116 °C | |
| MSDS | Chinese USA | Flash Point | 87.9±18.4 °C | |
| Symbol |
GHS07 |
Signal Word | Warning | |
|
Novel N-phenyl-substituted thiazolidinediones protect neural cells against glutamate- and tBid-induced toxicity.
J. Pharmacol. Exp. Ther. 350(2) , 273-89, (2014) Mitochondrial demise is a key feature of progressive neuronal death contributing to acute and chronic neurological disorders. Recent studies identified a pivotal role for the BH3-only protein B-cell lymphoma-2 interacting domain death antagonist (Bid) for suc... |
|
|
Bioconversion of butyronitrile to butyramide using whole cells of Rhodococcus rhodochrous PA-34.
Appl. Microbiol. Biotechnol. 74(3) , 535-9, (2007) Butyramide is an important chemical commodity, which is used for the synthesis of hydroxamic acids and electrorheological fluids and for the preparation of beta-amodoorganotin compounds. The nitrile hydratase (Nhase) of Rhodococcus rhodochrous PA-34 catalyzed... |
|
|
Synthesis of uniform protein-polymer conjugates.
Biomacromolecules 6(6) , 3380-7, (2005) We have developed a novel technique to synthesize near-uniform protein-polymer conjugates by initiating atom transfer radical polymerization of monomethoxy poly(ethylene glycol)-methacrylate from 2-bromoisobutyramide derivatives of chymotrypsin (a protein-ini... |
|
|
A microreactor for the study of biotransformations by a cross-linked gamma-lactamase enzyme.
Biotechnol. J. 4(4) , 510-6, (2009) A (+)-gamma-lactamase was precipitated, cross-linked and the resulting solid crushed prior to immobilisation within a capillary column microreactor. The microreactor was subsequently used to study enzyme stability, activity, kinetics and substrate specificity... |
|
|
Synthesis of N4-(2-acetamido-2-deoxy-beta-D-glucopyranosyl)-L-asparagine analogues. n-Butyramide, 3-chloropropionamide, 3-aminopropionamide, and isovaleramide analogues.
Carbohydr. Res. 331(4) , 439-44, (2001) The syntheses of four analogues of N4-(2-acetamido-2-deoxy-beta-D-glucopyranosyl)-L-asparagine are described. Activated carboxylic acids were reacted with 2-acetamido-2-deoxy-beta-D-glucopyranosylamine. n-Butyric anhydride gave N-(2-acetamido-2-deoxy-beta-D-g... |
|
|
Discordant effects of butyrate analogues on erythroleukemia cell proliferation, differentiation and histone deacetylase.
Anticancer Res. 15(3) , 879-83, (1995) Actions of butyrate and structural analogues on histone deacetylase activity were compared with effects on proliferation and differentiation of erythroleukemia cells. Proliferation was inhibited by 5 mM tert- butylacetate, phenylacetate, phenylbutyrate, 3-bro... |
|
|
Reduction of site-specific CYP3A-mediated metabolism for dual angiotensin and endothelin receptor antagonists in various in vitro systems and in cynomolgus monkeys.
Drug Metab. Dispos. 35(5) , 795-805, (2007) 2-{Butyryl-[2'-(4,5-dimethyl-isoxazol-3-ylsulfamoyl)-biphenyl-4-ylmethyl]-amino}-N-isopropyl-3-methyl-butyramide (BMS-1) is a potent dual acting angiotensin-1 and endothelin-A receptor antagonist. The compound was subject to rapid metabolic clearance in monke... |
|
|
Effect of butyrate analogues on proliferation and differentiation in human neuroblastoma cell lines.
Anticancer Res. 18(2A) , 1099-103, (1998) Butyric acid has been shown in vitro to produce cytodifferentiation of a wide variety of neoplastic cells. The potential clinical use of this compound as a therapeutic agent is limited by its rapid metabolism. This has led to the examination, as potential ant... |
|
|
An experiment in enzyme evolution. Studies with Pseudomonas aeruginosa amidase.
Biosci. Rep. 8(2) , 103-20, (1988) The regulation of amidase synthesis in P. aeruginosa is under positive control. This review describes the experimental evolution of amidase and its regulator protein for the hydrolysis of novel substrates and experiments to elucidate the mechanism of the cont... |
|
|
3-[2-((2S)-2-cyano-pyrrolidin-1-yl)-2-oxo-ethylamino]-3-methyl-butyramide analogues as selective DPP-IV inhibitors for the treatment of type-II diabetes.
Bioorg. Med. Chem. Lett. 17(5) , 1274-9, (2007) Based on the structures of NVP-DPP728 (1) and NVP-LAF237 (Vildagliptin, 2), three series of DPP-IV inhibitors were synthesized by linking substituted anilines, benzylamines, and phenylethylamines to (2S)-cyanopyrrolidine through a linker. More than 20 compoun... |